

## Topical Therapy of Xeroderma Pigmentosa with 20% Zinc Sulfate Solution

Khalifa E. Sharquie \* , Adil A.Noaimi\*\* , Nabeel O. Kadir\*\*\*

### ABSTRACT:

#### BACKGROUND:

Xeroderma pigmentosa although it is autosomal recessive disease but it is not uncommon problem in a certain regions in Iraq. It is always associated with well known complications of the disease like malignancies and blindness. Zinc sulfate has been successfully used in treatment of basal cell carcinoma in a form of intralesional injection & topical solution.

#### OBJECTIVE:

To evaluate the effectiveness of topical 20% zinc sulfate solution as a therapeutic and prophylactic agent in patients with xeroderma pigmentosa.

#### METHODS:

This single blind therapeutic trial was done in the Department of Dermatology & Venereology- Baghdad Teaching Hospital during the period from April 2004 to April 2005. Nineteen patients with typical features of xeroderma pigmentosa enrolled in this work. Full history and clinical examination were done for each patient regarding all points related to the disease. They were treated with topical 20% topical zinc sulfate solution and follow up was carried out for 4 months to 2 years.

#### RESULTS:

Nineteen patients with xeroderma pigmentosa were evaluated after treated with 20% topical zinc sulfate solution. Four patients were defaulted during follow up for unknown reason. The remaining were 15 patients (11 males and 4 females). Their ages ranged from 4-50 years with a mean± SD of 18 ±17 years. Monthly follow up showed improvement in all types of skin lesions including softening and lightening of the skin color, and clearance of solar keratosis and small malignancies. These were observed in the early course of therapy.

#### CONCLUSION:

This study showed that topical therapy with zinc sulfate solution had both therapeutic and prophylactic role in patients with xeroderma pigmentosa .We think that zinc sulfate is going to have a major role in management of this disease.

**KEYWORDS:** topical therapy, xeroderma pigmentosa, zinc sulfate.

### INTRODUCTION:

Xeroderma pigmentosum is a rare autosomal recessive disease with sun sensitivity, photophobia, early onset of freckling (pigmentary changes), and premature skin aging and subsequent neoplastic changes. There is cellular hypersensitivity to ultraviolet (UV) radiation and to certain chemicals in association with abnormal DNA repair<sup>(1-6)</sup>. It is more common in Japan and Middle East, but patients were reported worldwide in all races

including white Asians, blacks, Native Americans, it is relatively common in societies including Iraq ,when consanguineous marriages is common<sup>(1,3,6,7)</sup>.

Approximately half of the patients with xeroderma pigmentosum have a history of acute sunburn reaction on minimal UV exposure. All patients have numerous freckles like hyperpigmentation macules<sup>(1-4,6)</sup>. The median age of onset of the cutaneous symptoms is between 1-2 years. Continuous sun exposure causes the patient skin to become dry and parchment-like with increased pigmentation<sup>(1-4,6)</sup>. The premalignant actinic keratosis developed at an early age. Patients under the age of 20 years of age have greater than 100 fold increased risk of cutaneous basal cell carcinoma, squamous cell carcinoma or melanomas<sup>(5)</sup>. The median age of onset of non-melanoma skin cancer reported in patient with xeroderma pigmentosum was 8 years<sup>(5)</sup>.

\*Chairman of Scientific Council of Dermatology & Venereology-Iraqi Board for Medical Specializations.

\*\*Department of Dermatology & Venereology, College of Medicine, University of Baghdad.

\*\*\*Department of Dermatology & Venereology, College of Medicine, University of Kirkuk.

## XERODERMA PIGMENTOSA

---

The patients with xeroderma pigmentosum should adopt a life style to minimize UV exposure and use sunscreens with high sun protection factor (SPF) ratings (SPF 15 daily)<sup>(1,2,8-10)</sup>. Cells from patients with xeroderma pigmentosum are hypersensitive to killing with UVC, UVB and UVA. Patients should be examined frequently by a family member who has been instructed in recognition of cutaneous neoplasms<sup>(1,2,8,9)</sup>.

A bacterial DNA repair enzyme, den V T4 endonuclease, in a topical liposome containing preparation has been reported to reduce the frequency of new actinic keratosis and basal cell carcinoma in xeroderma pigmentosum patient in one research study<sup>(11)</sup>.

Several chemoprevention strategies are potentially helpful in suppressing the occurrence of skin cancers in many diseases like xeroderma pigmentosa, epidermodysplasia verruciformis, solid organ transplant, eruptive keratoderma, HIV/AIDS or even chronic wound or ulcers<sup>(12-14)</sup>.

Such therapies may act by treating premalignant lesions such as actinic keratosis, promoting cellular differentiation, competitively inhibiting oncogenes and photocarcinogenesis. Many drugs have been used orally or topically like retinoid, 5-fluorouracil, adapalen, imiquimod, photodynamic therapy, celecoxib & sunscreen<sup>(12-20)</sup>. In a recent study they used oral retinoid in treatment of skin cancers in patients with kidney transplant<sup>(13, 21, 22)</sup>.

There is no effective prophylactic (preventive) and therapeutic modalities for xeroderma pigmentosum<sup>(1-2,8)</sup>.

Zinc is an important essential micronutrient element for more than 300 metalloenzymes. All body tissue contains zinc and it is in the skin 5-6 times more concentrated in the epidermis than the dermis. serving as either a cofactors or an essential component of those enzymes such as alkaline phosphatase carbonic anhydrase and some dehydrogenase therefore it closely involve with protein synthesis and energy production<sup>(23)</sup>. So zinc is an important antioxidant agent, protect against UV radiation, enhance wound healing, contribute to immune functions and decrease the relative risk of skin cancers<sup>(24)</sup>. Also it serves as catalyst for enzymes responsible for DNA replication, gene transcription, and RNA and protein synthesis. Also zinc augment apoptosis and in a high concentration acts as a cytotoxic agent<sup>(25-27)</sup>. Apoptosis, a form of programmed cell death, is characterized by cell shrinkage and fragmentation. Apoptosis plays a vital role in the elimination of anti-self clones, down regulation of immune responses and the killing of virally infected and malignant cells<sup>(26-30)</sup>.

Furthermore, apoptosis occurs upon excessive UV light exposure, resulting in irreparable DNA damage. Mutation of p53 or over expression of bcl-2 is sufficient to enhance the formation of basal cell carcinoma by suppressing apoptosis<sup>(26,31)</sup>.

Many currently used antineoplastic agents exert their therapeutic effects through the induction of apoptosis. Different cell types vary profoundly in their susceptibility, suggesting the existence of distinct cellular thresholds for apoptosis induction<sup>(32)</sup>. In basal cell carcinoma, interferon- $\alpha$  and imiquimod induce apoptosis and is thus effective in the treatment<sup>(33)</sup>.

Topical zinc ions traverse skin and can be found in dermis and blood<sup>(34)</sup>, and found concentration could be increased in skin eightfold by topical application of zinc sulfate<sup>(24)</sup>. Also topical zinc sulfate or zinc chloride has been shown to protect skin of mouse against UVA and UVB induced sunburn<sup>(35)</sup>. Topical application of zinc ions has been shown to induce metallothionin, which may account for some effect<sup>(24)</sup>.

Oral zinc sulfate solution has been successfully tried in the treatment of cutaneous leishmaniasis, rosacea and viral warts<sup>(29, 36, 37)</sup>. Also, as (2%) intralesional mode used in cutaneous leishmaniasis, basal cell carcinoma and viral warts<sup>(26, 28, 38)</sup>.

Also, topical solution (10%) and (20%) was effectively used for plane warts and basal cell carcinoma subsequently<sup>(30)</sup>. (Sharquie KE 2006 personal communication). Most recently we have tried topical solution (20%) in a number of patients with xeroderma pigmentosa, which showed its effectiveness in controlling skin lesions. These results encouraged us to conduct the present work.

The aim of the present work is to evaluate the effectiveness of topical 20% zinc sulfate solution as a therapeutic and prophylactic agent in patients with xeroderma pigmentosa and to review the literatures regarding this problem.

### **PATIENTS AND METHODS:**

This single blind therapeutic trial was conducted in the Department of Dermatology & Venereology-Baghdad Teaching Hospital during the period from April 2004 to April 2005. Nineteen patients with typical features of xeroderma pigmentosa were enrolled in this work. A detailed history was taken from each patient or their parents regarding the following points: age, gender, address, family history, age of onset, outdoor activities, duration of the disease, drug history, and history of surgical interventions.

Thorough full clinical examination was performed for each patient to assess the distribution and extent and morphology of the skin lesions and to categorized it accordingly. Also to report eye

## XERODERMA PIGMENTOSA

involvement and other organ association.

Any patient with large size (more than 1.5 cm in diameter) skin malignancy and their location near to the vital organs or need urgent surgical intervention was excluded.

All patients included in the present work had no history of treatment with topical or systemic remedies for at least two months before starting therapy.

For each patient or their parents a formal consent was taken after full explanation regarding: nature of disease, course, methods of treatment, duration, follow up and prognosis before the start the therapy. Also the ethical approval was performed by the scientific committee of the Scientific Council of Dermatology & Venereology-Iraqi Board for Medical Specializations.

A photograph was taken at the initial and subsequent visits by a mercury digital camera cyberplx S-450V at the same place and a fixed illumination.

A solution of 20% w/v zinc sulfate was prepared by dissolving 20 grams of zinc sulfate ( $ZnSO_4 \cdot 7H_2O$ ) from British Drug house, Pool, England) in 100cc of distilled water. This was applied as a topical solution twice a day and followed every month. The follow-up time was ranged from 4 months to 2 years.

### RESULTS:

Nineteen patients with xeroderma pigmentosa treated with topical 20% zinc sulfate solution were

evaluated. Four patients defaulted during follow up for unknown reason. The remaining were 15 patients (11 males, 4 females). Their ages ranged

from 4-50 years with a mean  $\pm$  SD of  $18 \pm 17$  years while the age of onset were ranged 2-14 years with a mean  $\pm$  SD of  $1.5 \pm 0.9$  years. The family history was positive in 13 (86.6%) patients only.

Sixteen (73.6%) patients had history of surgical excision of multiple basal cell carcinoma, while 12 (63.1%) patients gave history of treatable keratoacanthoma. Also history of removing solar keratosis in 12 (63.1%) patients and squamous cell carcinoma in 6 (31.5%) cases.

All patients had classical picture of xeroderma pigmentosa on the exposed parts of the body mainly face and neck with eye involvements. Photophobia and freckling were present in all patients (100%). On examination the skin lesions were freckling, dryness, roughness, scars of previous surgical intervention in 14 (73.6%) cases, solar keratosis with small malignancies (not more than 1.5 cm) as follow: basal cell carcinoma in 16 (73.6%) patients, keratoacanthoma in 6 (31.5%) cases, solar keratosis in 10 (52.6%) patients and squamous cell carcinoma in 4 (21.05%) cases.

Most patients received no important medical therapies apart from zinc oxide cream in some of them as sunscreen.

Monthly follow up showed improvement in all types of skin lesions including softening and lightening of the skin color, and clearance of solar keratosis and small malignancies. These were observed in the first three months of course of therapy.

Patients on longer follow up to 2 years and in continuous therapy developed no exacerbation of old lesions and no new malignancies were seen.



Figure 1: Showing 8 years old male patient with xeroderma pigmentosa before using 20% zinc sulfate solution.

Figure 2(a,b): Showing 8 years old male patient with xeroderma pigmentosa after 2 months of using therapy, revealed clearance of old lesions, no photophobia and no new lesions.

### DISCUSSION:

Skin cancers are a major health problem in many countries and knowing that nearly one to five Americans will develop skin cancer in their lifetime. It is not surprising that the prevention of cutaneous malignancies through the use of oral or topical chemopreventive measures, is of significant interest to the dermatologist and their patients especially in high risk individuals like those with a history of iatrogenic, acquired or inherited immune deficiency, a genodermatosis such as xeroderma pigmentosa or Gorlin's disease, radiation exposure, chronic ulcer or wound, eruptive keratoacanthoma, leukoplakia, or a marked history of sun exposure, sun burn and solid organ transplant<sup>(12-14,21,22)</sup>.

Many chemicals and drugs orally or topically have been tried in prevention and controlling skin malignancies like retinoid, 5-fluorouracil, adapalen, imiquimod, photodynamic therapy, celecoxib & sunscreen re<sup>(12-22)</sup>.

Xeroderma pigmentosa is a natural product of gene repair defect which is inherited as an important skin problem<sup>(1-6)</sup>; it is relatively common in societies with high blood related marriages including Iraq<sup>(1-3, 6,7)</sup>.

They are often neglected and all of them practice outdoor activities, ending with a high malignancies and blindness followed by a high mortality rate. So essential measures should be taken to prevent the progression of the disease including: indoor activity, using sunscreen and taking chemopreventive chemicals and drugs<sup>(1, 2, 8-10)</sup>.

Using 2% zinc sulfate solution as intralesional therapy for basal cell carcinoma has encouraged us to conduct the present work<sup>(26)</sup>. Also topical 20% zinc sulfate solution was successful therapy when preliminary study done in patients with basal cell carcinoma and solar keratosis.

The present work showed that topical zinc sulfate solution is effective in clearing and preventing the lesions in xeroderma pigmentosa patients.

The mechanism of action of zinc in xeroderma pigmentosa is not well known but probably through the following established effects of zinc: enhance wound healing, antioxidant, sunscreen, decrease cancer, protection against UV radiation, enhance DNA repair, improve immunity, accelerate apoptosis and locally might act as cytotoxic drug<sup>(23-37)</sup>.

The important question to be raised is whether zinc sulfate as oral therapy or eye preparations will be effective in controlling skin and eye problems or not, so further studies and long term follow up are essentially needed.

### CONCLUSION:

Topical zinc sulfate solution is a new chemopreventive agent through its therapeutic and prophylactic effects as shown to be successful in controlling skin lesions in patient with xeroderma pigmentosa. Further evaluations are strongly recommended especially with a higher concentration, to expand our experience with this drug in treatment patient suffering from xeroderma pigmentosa.

### REFERENCES:

1. Wenstrap RJ and Zhao H. Heritable Diseases of Connective Tissues with Skin Changes. Fitzpatrick's Dermatology In General Medicine, 6<sup>th</sup> Ed., Freedberg IM, Eisen AZ, Wolffk K, Austen KF, Goldsmith LA & Katz SI, New York, McGraw-Hill, 2003; 154,1496-1507.
2. Burton JI & Lovell CR. Disorders of Connective Tissue. In Textbook of Dermatology, vol.3, 6<sup>th</sup> Ed. Champion RH, Burton JI, Burns DA & Breathmath SM, Oxford Blackwell 1998; 44,2003-2071.
3. Pawsey SA, Magnus IA, Ramsay CA et al. Clinical, genetic, and DNA repair studies on a consecutive series of patients with xeroderma pigmentosum. *Q J Med* 1997; 48, 179-210.
4. Kraemer, KH; Lee, MM; Scotto, J. Xeroderma pigmentosum: Cutaneous, ocular and neurologic abnormalities in 830 published cases. *Arch-Dermatol*. 1987; 123,241-50.
5. Stein, HJ; Kraemer, SJ; Feussner, H; Siewert, JR, The role of sunlight and DNA repair in melanoma and non melanoma skin cancer. The xeroderma pigmentosum paradigm. *Arch Dermatol* 1994; 130,1018.
6. Sharquie KE & Mancy A. Xeroderma pigmentosum, Clinical and epidemiological study in Al-Ramadi city. *J Fac Med Baghdad* 1997; 39, 241-5.
7. Al-Hamami HA, Al-Bayati NM and Al-Kubiasie W. Consanguineous Marriages in the Iraqi Urban Population and the effect on pregnancy outcome & infant mortality. *Iraqi Med. J*. 1986; 34, 72-75.
8. Lim HW, Cooper K. The health impact of solar radiation and prevention strategies. *J Amer Acad Dermatol*. 1999; 41, 81-99.
9. Kligman LH, Akin FJ, Kligman AM. Sunscreens prevent ultraviolet photocarcinogenesis. *J Am Acad Dermatol*. 1980; 3,30-35.

## XERODERMA PIGMENTOSA

---

10. Pinnell S. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. *J Am Acad Dermatol.* 2003; 48,1-19.
11. Yarosh, D; Klein, J; O'Connor, A; Hawk, J; Rafal, E; Wolf, P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum in randomized study: Xeroderma pigmentosum Study Group. *Lancet.* 2001; 357,926-9.
12. DiGiovanna J. Retinoid chemoprevention in the high-risk patient. *J Am Acad Dermatol.* 1998; 39,S82-S85.
13. Bavinck, JN; Tieben, LM; Van-der-Woude, FJ; Tegzess, AM; Hermans, J; ter-Schegget, J; Vermeer, BJ., Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double blind, placebo-controlled study. *J Clin-Oncol.* 1995; 13,1933-8.
14. Bercovitch L. Topical chemotherapy of actinic keratoses of the upper extremity with tretinoin and 5-fluorouracil: a double blind controlled study. *Br J Dermatol.* 1987; 116,549-552.
15. Peck GL. Topical tretinoin in actinic keratosis and basal cell carcinoma. *J Am Acad Dermatol.* 1986; 15, 829-835.
16. Kang, S; Goldfarb, MT; Weiss, JS; Metz, RD; Hamilton, TA; Voorhees, JJ; Griffiths, CE., Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: A randomized trial. *J Am Acad Dermatol.* 2003 ; 49, 83-90.
17. Jeffes, EW; McCullough, JL; Weinstein, GD; Fergin, PE; Nelson, JS; Shull, TF; Simpson, KR; Bukaty, LM; Hoffman, WL; Fong, NL. , Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: A pilot dose-ranging study. *Arch Dermatol.* 1997 ; 133, 727-32.
18. Wilgus T, Breza TS, Tober KL, Oberyshyn TM. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. *J Invest Dermatol.* 2004; 122, 1488-1494.
19. FDA statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex [FDA Website]. December 17, 2004. Available at: <http://www.fda.gov/bbs/topics/news/2004/new01144.html>. Accessed December, 20, 2004.
20. Kraemer, KH; DiGiovanna, JJ; Moshell, AN; Tarone, RE; Peck, GL. Prevention of skin cancer in xeroderma pigmentosum with use of oral isotretinoin. *N-Engl-J-Med.* 1988; 318, 1633-7.
21. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. *J Am Acad Dermatol.* 2001; 45, S150-S157.
22. Levine N. Role of retinoids in skin cancer treatment and prevention. *J Am Acad Dermatol.* 1998; 39, S62-S66.
23. Bennett GR. Zinc deficiency. In Bennett GR. Fundamentals of cutaneous surgery 1st edition 1988, C. V. Mosby company 702-705.
24. Elizabeth F. Evidence supporting zinc as an important antioxidant for skin. *Int J Dermatol* 2002; 41,606-615.
25. Environmental health criteria. World health organization, (22) Zinc. Geneva 2001, Metabolic role P 17.
26. Sharquie KE, Al-Nuaimy AA, Al-Shimary FA. New Intralesional therapy for basal cell carcinoma by 2% zinc sulfate solution. *Saudi Med J.* 2005; 26,359-61.
27. Wyllie AH, Kerr JF, Currie AR. Cell death: The significance of Apoptosis. *Int Rev Cytol*, 1980; 68,251-306.
28. Sharquie KE and Al-Nuaimy A. Treatment of viral warts by intralesional injection of zinc sulfate 2%. *Annals Saudi Med* 2001; 22,26-28.
29. Al- Gurairi FT, Al-Waiz MM, Sharquie kE. Oral zisulphate in the treatment of recalcitrant viral warts, randomized placebo-controlled clinical trial. *BrJ Dermatol* 2002 ;146 , 423-431.
30. Sharquie KE, Khorsheed AA and Al-Nuaimy A. Topical zinc sulphate solution for treatment of viral warts. *Saudi Med J.* 2007; 28,477-80.
31. Wikonkal NM, Berg RJW, van Haselen CW. Bcl-2 versus P53 protein Expression and Apoptotic rate in Human Non-Melanoma Skin Cancers. *Arc Dermatol* 1997; 133,599-602.
32. Fisher DE. Apoptosis in Cancer Therapy: Crossing the Threshold. *Cell* 1994; 78,539-42.
33. Rodriguez VJ and McDonnell TJ. Induction of Apoptotic Cell Death in Non-melanoma Skin Cancer by Interferon-alpha. *Int J Cancer* 1995; 61,110-4.
34. Hallmans G, Lindens. Penetration of 65 zinc through the skin of rat. *Acta Derm Venereo* 1979; 59,105-112.
35. Record IR. Protection by zinc against UVA and UVB induced cellular and genomic damage in vivo and in vitro. *Biol Trace Elem Res.* 1996;53,19-25.
36. Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. *Clinical and experimental dermatology* 2001 ;26,21-25.

## XERODERMA PIGMENTOSA

---

37. Sharquie KE ,Najim RA.& Al –Salman HN.Oral Zinc Sulphate in the Treatment of Rosacea.A Double Blind placebo–controlled cross–over study.JEADV, ;2005 October; 19(suppl 2).
38. Sharquie KE, Al-Azzawi KK. Intralesional Therapy of Cutaneous Leishmaniasis with 2% zinc sulfate solution. J Pan-Arab League Dermatol 1996; 7,41-9.